Literature DB >> 25520864

miR-199a-3p negatively regulates the progression of osteosarcoma through targeting AXL.

Rui Tian1, Xianbiao Xie2, Ju Han1, Canqiao Luo1, Bicheng Yong2, Huizhi Peng1, Jingnan Shen2, Tingsheng Peng1.   

Abstract

Dysregulation of micro-RNAs has been shown to contribute to multiple tumorigenic processes, as well as to correlate with tumor progression and prognosis. miR-199a has been shown to be dysregulated in many different tumor types; however, the association between miR-199a and the clinicopathological features of osteosarcoma is unknown, and the target gene for miR-199a and the regulatory mechanism are also unknown. In this study, we demonstrated that miR-199a-3p is expressed at low levels in osteosarcoma cells, which may inhibit the migration and invasion of these tumor cells. The downregulation of miR-199a-3p expression is significantly correlated with the recurrence and lung metastasis of patients with osteosarcoma. Using multivariate Cox regression analysis, low level of expression of miR-199a-3p was shown to be an independent predictor for worse prognosis in osteosarcoma. Furthermore, we showed that miR-199a-3p mimics can decrease the expression of the mRNA and protein of the receptor tyrosine kinase AXL, and miR-199a-3p targets directly the 3'-UTR of AXL mRNA, suggesting that miR-199a-3p may downregulate the expression of the AXL gene to inhibit the progression of osteosarcoma. In patients' osteosarcoma samples, we also showed a statistically significant inverse relation between the levels of miR-199a-3p and AXL, which is consistent with the results in osteosarcoma cell lines. Interestingly, miR-199a-3p mimics reduced the level of phosphorylation of AKT. Together with the previous data, we conclude that miR-199a-3p negatively contributes to the progression of osteosarcoma by downregulating the expression of AXL mRNA and protein. By this mechanism, a regulatory pathway comprised of miR-199a-3p and AXL may exist in osteosarcoma cells, which may as a result regulate the progression of osteosarcoma through the AKT pathway.

Entities:  

Keywords:  AXL; Osteosarcoma; invasion; miR-199a-3p; migration; prognosis

Year:  2014        PMID: 25520864      PMCID: PMC4266708     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  23 in total

1.  MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1.

Authors:  Jian-Qiang Xu; Ping Liu; Ming-Jue Si; Xiao-Yi Ding
Journal:  Tumour Biol       Date:  2013-07-24

2.  MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN.

Authors:  Lei Shen; Xiao-Dong Chen; Yao-Hui Zhang
Journal:  Tumour Biol       Date:  2013-10-15

3.  Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.

Authors:  Ju Han; Rui Tian; Bicheng Yong; Canqiao Luo; Pingxian Tan; Jingnan Shen; Tingsheng Peng
Journal:  Biochem Biophys Res Commun       Date:  2013-05-15       Impact factor: 3.575

4.  microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women.

Authors:  Weiwei Cheng; Te Liu; Feizhou Jiang; Chunmin Liu; Xinrong Zhao; Yongtao Gao; Hui Wang; Zhixue Liu
Journal:  Int J Mol Med       Date:  2011-01-13       Impact factor: 4.101

5.  Location of pulmonary metastasis in pediatric osteosarcoma is predictive of outcome.

Authors:  Phillip A Letourneau; Lianchun Xiao; Matthew T Harting; Kevin P Lally; Charles S Cox; Richard J Andrassy; Andrea A Hayes-Jordan
Journal:  J Pediatr Surg       Date:  2011-07       Impact factor: 2.545

6.  MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell.

Authors:  Zhu Jianwei; Liu Fan; Liu Xiancheng; Bai Enzhong; Li Shuai; Li Can
Journal:  Tumour Biol       Date:  2013-06-06

7.  Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma.

Authors:  Zhigang Wang; Haikang Cai; Lijun Lin; Mingjie Tang; Haiqing Cai
Journal:  Pediatr Blood Cancer       Date:  2013-09-09       Impact factor: 3.167

8.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

9.  miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells.

Authors:  Yong Wang; Wei Zhao; Qin Fu
Journal:  Mol Cell Biochem       Date:  2013-08-22       Impact factor: 3.396

10.  Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway.

Authors:  Yan Zhang; Kai-Ji Fan; Qiang Sun; Ai-Zhong Chen; Wen-Long Shen; Zhi-Hu Zhao; Xiao-Fei Zheng; Xiao Yang
Journal:  Nucleic Acids Res       Date:  2012-07-19       Impact factor: 16.971

View more
  26 in total

1.  MicroRNA-135b regulates apoptosis and chemoresistance in colorectal cancer by targeting large tumor suppressor kinase 2.

Authors:  Yuqi He; Jianxun Wang; Jiheng Wang; Victoria Yee-Wa Yung; Emily Hsu; Aiqin Li; Qian Kang; Junbiao Ma; Qingfeng Han; Peng Jin; Rui Xing; Youyong Lu; Jianqiu Sheng
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

2.  miR-199a-5p regulates HIF-1α and OSGIN2 and its expression is correlated to soft-tissue sarcoma patients' outcome.

Authors:  Jacqueline Keßler; Swetlana Rot; Matthias Bache; Matthias Kappler; Peter Würl; Dirk Vordermark; Helge Taubert; Thomas Greither
Journal:  Oncol Lett       Date:  2016-10-26       Impact factor: 2.967

3.  MicroRNA-199a-3p attenuates hepatic lipogenesis by targeting Sp1.

Authors:  Yang Cheng; Li Huang; Jian Ping; Tianyang Chen; Jianjie Chen
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

4.  Long noncoding RNA LeXis promotes osteosarcoma growth through upregulation of CTNNB1 expression.

Authors:  Guijiang Wang; Tao Cui; Lishan Sun; Ningning Peng; Cheng Yang
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

5.  MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of BRCA1.

Authors:  John Chi-Wang Ho; Jiawei Chen; Isabella Wai-Yin Cheuk; Man-Ting Siu; Vivian Yvonne Shin; Ava Kwong
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 6.  Targeting protein kinases to reverse multidrug resistance in sarcoma.

Authors:  Hua Chen; Jacson Shen; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2015-12-08       Impact factor: 12.111

7.  CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.

Authors:  Yan Gao; Yong Feng; Jacson K Shen; Min Lin; Edwin Choy; Gregory M Cote; David C Harmon; Henry J Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Sci Rep       Date:  2015-06-16       Impact factor: 4.379

8.  Integrative radiogenomic analysis for multicentric radiophenotype in glioblastoma.

Authors:  Doo-Sik Kong; Jinkuk Kim; In-Hee Lee; Sung Tae Kim; Ho Jun Seol; Jung-Il Lee; Woong-Yang Park; Gyuha Ryu; Zichen Wang; Avi Ma'ayan; Do-Hyun Nam
Journal:  Oncotarget       Date:  2016-03-08

9.  Circular RNA circNRIP1 plays oncogenic roles in the progression of osteosarcoma.

Authors:  Yibin Meng; DingJun Hao; YunFei Huang; ShuaiJun Jia; JiaNan Zhang; XiRui He; Deyin Liu; Liang Sun
Journal:  Mamm Genome       Date:  2021-07-10       Impact factor: 2.957

10.  Serum microRNA-199a/b-3p as a predictive biomarker for treatment response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Zelong Luo; Chao Feng; Peng Hu; Yong Chen; Xiao-Feng He; Yanhao Li; Jianbo Zhao
Journal:  Onco Targets Ther       Date:  2016-05-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.